title: Circulating tumor cells count and characterization in a male breast cancer patient.
abstract: A 64-y-old man presented to Medical Oncology Department a metastatic invasive ductal breast carcinoma, positive for estrogen (ER) and progesterone receptors (PR) and Her2/neu negative. The patient was treated with different lines of therapy, with rapid radiological progression of disease. After four courses of a third-line chemotherapy, a radiological stable disease was maintained. The patient was followed by serial blood drawings for the characterization and count of circulating tumor cells (CTC). This is the first report concerning the predictive and prognostic value of CTC in a male breast cancer patient.
authors: Department of Molecular Medicine,apienza University of Rome, Rome, Italy. paola.gazzaniga@uniroma1.it
authors: Paola
authors: P
authors: Gazzaniga
authors: Giuseppe
authors: G
authors: Naso
authors: Cristina
authors: C
authors: Raimondi
authors: Angela
authors: A
authors: Gradilone
authors: Antonella
authors: A
authors: Palazzo
authors: Orietta
authors: O
authors: Gandini
authors: Arianna
authors: A
authors: Petracca
authors: Chiara
authors: C
authors: Nicolazzo
authors: Enrico
authors: E
authors: Cortesi
authors: Luigi
authors: L
authors: Frati
mesh_terms: D018567:Breast Neoplasms, Male / Q000097:blood* / Q000188:drug therapy*; D016190:Carboplatin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018270:Carcinoma, Ductal, Breast / Q000097:blood* / Q000188:drug therapy*; D002452:Cell Count; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D015251:Epirubicin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000187:drug effects*; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis; D043823:Taxoids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D016190:Carboplatin; D003841:Deoxycytidine; D000077143:Docetaxel; D015251:Epirubicin; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D043823:Taxoids; D000093542:Gemcitabine; C508053:ERBB2 protein, human